GlycoSyn offers the glycopeptide building blocks needed for effective cancer vaccines
Glycosylation of the MUC1-peptide antigen component of a fully synthetic tripartite cancer vaccine proved to be a critical requirement for triggering an effective response involving both humoral and cellular immune responses.
The vaccine candidate, developed by Professor Geert-Jan Boons at the Complex Carbohydrate Research Centre at the University of Georgia and collaborators at the Mayo Clinic, is composed of covalently bound immunoadjuvant Pam3CysSK4, a peptide Thelper epitope and an aberrantly glycosylated MUC1-peptide. It caused a significant reduction in tumor burden in a humanized mouse model of mammary cancer.
The αGalNAc modified glycopeptide component was synthesised by Fmoc-solid phase synthesis using Fmoc-L-Thr(α-D-GalNAc(Ac)3)-OH.
Read the original article:
Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine, V. Lakshminarayanan, P. Thompson, M. A. Wolfert, T. Buskas, J. M. Bradley, L. B. Pathangey, C. S. Madsen, P. A. Cohen, S. J. Gendler, G.-J. Boons, PNAS 2012, 109, 1, 261-266.
Fmoc-L-Thr(α-D-GalNAc(Ac)3)-OH is one of the glycosylated amino acids available in our GlycoSyn catalogue. We offer a wide range of building blocks ready for use in Fmoc-solid phase peptide synthesis and for further chemical modification. Combining world class expertise in carbohydrate and glycopeptide synthesis we are your partner for development of complex derivatives and we are happy provide you a quote for custom synthesis.